Form 4: Coherus BioSciences CEO Acquires 575,000 Stock Options

Coherus BioSciences CEO, Dennis M. Lanfear, was granted 575,000 stock options on January 10, 2025, according to a recent SEC filing.

Summary

• Dennis M. Lanfear, the President and CEO of Coherus BioSciences, Inc., was granted 575,000 stock options on January 10, 2025.
• These options have an exercise price of $1.47 per share.
• The options vest over a four-year period, with 25% vesting on the one-year anniversary of the grant date and the remaining 75% vesting in equal monthly installments over the following three years.
• The options expire on January 10, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.

Positives

• The grant of stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry.
• The vesting schedule of 4 years with a 1 year cliff is a common vesting schedule for stock options.
• The exercise price of $1.47 is a common price for stock options.

Stakeholder Impact

• The stock option grant could positively impact shareholder value if the CEO's performance leads to an increase in the company's stock price.

Key Dates

Keywords

stock options, SEC Form 4, insider trading, executive compensation, Coherus BioSciences, Dennis M. Lanfear